I
Ing Soo Tiong
Researcher at Monash University
Publications - 59
Citations - 1731
Ing Soo Tiong is an academic researcher from Monash University. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 15, co-authored 35 publications receiving 1016 citations. Previous affiliations of Ing Soo Tiong include University of Otago & Alfred Hospital.
Papers
More filters
Journal ArticleDOI
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H. Wei,Stephen A. Strickland,Jing Zhou Hou,Walter Fiedler,Tara L. Lin,Roland B. Walter,Roland B. Walter,Anoop K Enjeti,Anoop K Enjeti,Ing Soo Tiong,Michael R. Savona,Sangmin Lee,Brenda Chyla,Relja Popovic,Ahmed Salem,Suresh Agarwal,Tu Xu,Kaffa Fakouhi,Rod A. Humerickhouse,Wan Jen Hong,John Hayslip,Gail J. Roboz +21 more
TL;DR: Venetoclax plus LDAC has a manageable safety profile, producing rapid and durable remissions in older adults with AML ineligible for intensive chemotherapy, and high remission rate and low early mortality combined with rapid and Durable remission make venetoclAX and LDAC an attractive and novel treatment for older adults not suitable forintensive chemotherapy.
Journal ArticleDOI
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Courtney D. DiNardo,Ing Soo Tiong,Ing Soo Tiong,A. Quaglieri,Sarah MacRaild,Sanam Loghavi,Fiona C. Brown,Rachel Thijssen,Giovanna Pomilio,Adam Ivey,Jessica M. Salmon,Christina Glytsou,Shaun Fleming,Shaun Fleming,Qi Zhang,Huaxian Ma,Keyur P. Patel,Steve Kornblau,Zhen Xu,Chong Chyn Chua,Chong Chyn Chua,Xufeng Chen,Piers Blombery,Piers Blombery,Piers Blombery,Christoffer Flensburg,Nik Cummings,Ioannis Aifantis,Hagop M. Kantarjian,David C.S. Huang,Andrew W. Roberts,Andrew W. Roberts,Ian J. Majewski,Marina Konopleva,Andrew H. Wei,Andrew H. Wei +35 more
TL;DR: Molecular determinants of outcome with clinical relevance to patients with AML receiving venetoclax-based combination therapies are identified, highlighting the dynamic and rapid occurrence of therapeutic selection in AML.
Journal ArticleDOI
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Donia M Moujalled,Donia M Moujalled,Giovanna Pomilio,Giovanna Pomilio,Corina Ghiurau,Adam Ivey,Jessica M. Salmon,Jessica M. Salmon,Sewa Rijal,Sarah MacRaild,Lan Zhang,Tse-Chieh Teh,Tse-Chieh Teh,Ing Soo Tiong,Ping Lan,Maïa Chanrion,Audrey Claperon,Francesca Rocchetti,Adrien Zichi,Laurence Kraus-Berthier,Y. Wang,Ensar Halilovic,Erick Morris,Frédéric Colland,David J. Segal,David C.S. Huang,David C.S. Huang,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts,Ana Leticia Maragno,Guillaume Lessene,Guillaume Lessene,Olivier Geneste,Andrew H. Wei,Andrew H. Wei +35 more
TL;DR: A dual BH3-mimetic approach is feasible, highly synergistic, and active in diverse models of human AML, with strong clinical potential to rapidly suppress leukemia, with reduced toxicity to normal hematopoietic precursors compared to chemotherapy.
Journal ArticleDOI
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chong Chyn Chua,Chong Chyn Chua,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts,John V. Reynolds,Chun Yew Fong,Stephen B. Ting,Jessica M. Salmon,Sarah MacRaild,Sarah MacRaild,Adam Ivey,Ing Soo Tiong,Ing Soo Tiong,Shaun Fleming,Shaun Fleming,Fiona C. Brown,Sun Loo,Ian J. Majewski,Ian J. Majewski,Stefan K. Bohlander,Andrew H. Wei,Andrew H. Wei +22 more
TL;DR: Although the optimal postremission therapy remains to be determined, the high remission rate in de novo AML warrants additional investigation (ANZ Clinical Trial Registry No. ACTRN12616000445471).
Journal ArticleDOI
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Andrew H. Wei,Ing Soo Tiong +1 more
TL;DR: A quintet of new drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33.